There has been no experience of overdosage in human clinical trials.

Because Abciximab may increase the risk of bleeding, Abciximab is contraindicated in the following clinical situations:

• Active internal bleeding
• Recent (within six weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance.
• History of cerebrovascular accident (CVA) within two years, or CVA with a significant residual neurological deficit
• Bleeding diathesis
• Administration of oral anticoagulants within seven days unless prothrombin time is ≤ 1.2 times control
• Thrombocytopenia ( < 100,000 cells/µL)
• Recent (within six weeks) major surgery or trauma
• Intracranial neoplasm, arteriovenous malformation, or aneurysm
• Severe uncontrolled hypertension
• Presumed or documented history of vasculitis
• Use of intravenous dextran before PCI, or intent to use it during an intervention Abciximab is also contraindicated in patients with known hypersensitivity to any component of this product or to murine proteins.

Last reviewed on RxList: 6/20/2008
This monograph has been modified to include the generic and brand name in many instances.